Open access · CC-BY
via OpenAlex
Metformin for Longevity and Sarcopenia: A Therapeutic Paradox in Aging
Song-Yi Han, Mukesh Kumar Yadav, Jing‐Hua Wang
Biomedicines · 2026 · ▲ 3 citations
Deregulated nutrient-sensing
Altered intercellular communication
Chronic inflammation
Rapamycin / mTOR inhibition
Metformin
Exercise
Partial reprogramming (OSK)
Abstract
Metformin is a first-line oral antidiabetic agent that has attracted increasing interest as a potential geroprotective therapy due to its ability to improve metabolic homeostasis, reduce oxidative stress, and attenuate chronic inflammation. However, its role in skeletal muscle aging and sarcopenia remains controversial. Observational and epidemiological studies suggest that metformin use is associated with a lower prevalence of sarcopenia, particularly in metabolically compromised or insulin-resistant older populations, where improvements in systemic metabolism and inflammatory burden may indirectly support muscle quality and function. In contrast, randomized interventional trials in metabolically healthy older adults indicate that metformin can blunt resistance exercise-induced muscle hypertrophy and protein synthesis, likely through sustained activation of AMP-activated protein kinase (AMPK) and consequent suppression of mammalian target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) complex 1 (mTORC1) signaling. This perspective argues that these apparently opposing outcomes reflect a con-text-dependent therapeutic paradox rather than inconsistent evidence. Metformin may provide metabolic protection in frail, insulin-resistant individuals, yet limit anabolic adaptations in physically active older adults. These findings emphasize the necessity for precision geropharmacological strategies to balance metabolic longevity with preservation of musculoskeletal health in aging populations.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3390/biomedicines14020376
- Canonical
- link ↗
- Fetched
- 2026-11-14 MST
Cite this
APA
Han, S., Yadav, M.K., & Wang, J. (2026). Metformin for Longevity and Sarcopenia: A Therapeutic Paradox in Aging. <em>Biomedicines</em>. https://doi.org/10.3390/biomedicines14020376
Vancouver
Han S, Yadav MK, Wang J. Metformin for Longevity and Sarcopenia: A Therapeutic Paradox in Aging. Biomedicines. 2026. doi:10.3390/biomedicines14020376.
BibTeX
@article{songyi2026Metfor,
title = {Metformin for Longevity and Sarcopenia: A Therapeutic Paradox in Aging},
author = {Song-Yi Han and Mukesh Kumar Yadav and Jing‐Hua Wang},
journal = {Biomedicines},
year = {2026},
doi = {10.3390/biomedicines14020376},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Nutrients 2018
Open access · CC-BY
Dietary Protein and Muscle in Aging People: The Potential Role of the Gut Microbiome
Journal of Education Health and Sport 2026
Open access · CC-BY
Metformin as a Potential Geroprotective Agent: Mechanisms, Clinical Evidence and Implications for Healthy Aging
International Journal of Environmental Sciences 2025
Open access · CC-BY
Metformin: Beyond Glycemic Control - A Comprehensive Review Of Its Adverse Effects And Emerging Therapeutic Potential
University of Jaén 2023
Open access · US-GOV
Effects of a Yoga Program Combined With Diet on Cognitive, Nutritional Status, Mental and Functional Abilities in Older Adults.
Frontiers in endocrinology 2026
Open access · OA
Muscle-brain crosstalk in sarcopenia and cognitive impairment: endocrine signaling, metabolic regulation, and exercise modulation.
International Journal of Environmental Research and Public Health 2026
Open access · CC-BY